VSTM
Verastem Inc
NASDAQ · Biotechnology
$6.67
+0.39 (+6.21%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 20.88M | 12.31M | 321.49M | 326.86M | 307.68M |
| Net Income | -272,747,664 | -144,736,378 | 10.36M | 9.66M | 8.39M |
| EPS | — | — | — | — | — |
| Profit Margin | -1,306.4% | -1,241.1% | 3.2% | 3.0% | 2.7% |
| Rev Growth | +69.6% | +69.6% | +4.8% | +8.0% | +1.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 84.03M | 84.03M | 131.11M | 137.11M | 136.03M |
| Total Equity | 164.63M | 164.63M | 170.78M | 172.31M | 166.34M |
| D/E Ratio | 0.51 | 0.51 | 0.77 | 0.80 | 0.82 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -271,442,830 | -152,046,396 | 16.17M | 19.14M | 17.15M |
| Free Cash Flow | — | — | 7.86M | 10.52M | 8.69M |